| Trial ID: | L6024 |
| Source ID: | NCT04260438
|
| Associated Drug: |
Ckd-501 0.5mg Tab. 1t, D759 100mg Tab. 1t And D150 1000mg Tab. 1t
|
| Title: |
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T|DRUG: CKD-393 0.5/100/1000mg formulation 1 Tab. 1T|DRUG: CKD-393 0.5/100/1000mg formulation 2 Tab. 1T
|
| Outcome Measures: |
Primary: AUCt of CKD-501, D759, D150, CKD-393, Area under the CKD-501/D759/D150/CKD-393 concentration in blood-time curve from zero to final, Time Frame: 0 hour ~ 48 hours|Cmax of CKD-501, D759, D150, CKD-393, The maximum CKD-501/D759/D150/CKD-393 concentration in blood sampling time t, Time Frame: 0 hour ~ 48 hours |
|
| Sponsor/Collaborators: |
Sponsor: Chong Kun Dang Pharmaceutical
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2020-04-08
|
| Completion Date: |
2020-06-24
|
| Results First Posted: |
|
| Last Update Posted: |
2021-04-30
|
| Locations: |
Korea University Anam Hospital, Seoul, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT04260438
|
